174P Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis

J. Balmana,P.A. Fasching, S. Delaloge,Y.H. Park, A. Eisen, H. Bourgeois, Z. Kemp, T. Jankowski,J. Sohn,S. Aksoy, C.V. Timcheva,T-W. Park-Simon,A. Anton Torres,E. John, K. Baria, G. Walker, K.A. Gelmon

Annals of Oncology（2022）

引用 2|浏览4

暂无评分

摘要

LUCY interim findings confirmed the clinical effectiveness of olaparib 300 mg twice daily in patients with metastatic breast cancer (mBC) in a real world setting. Findings were consistent with the OlympiAD trial of olaparib vs chemotherapy of physician’s choice. We report results of the final planned analysis.

查看译文

关键词

breast cancer,olaparib,clinical effectiveness,brca-mutated,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要